Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
EXELIXIS, INC. | Pres, Prod Dev & Med Aff & CMO | Common Stock | 689K | $15.8M | $22.86 | Jul 26, 2021 | Direct |
EXELIXIS, INC. | Pres, Prod Dev & Med Aff & CMO | Common Stock | 14.9K | $340K | $22.86 | Jul 26, 2021 | By 401(k) |
GENOCEA BIOSCIENCES, INC. | Director | Stock Option (Right to Buy) | 15K | Jul 1, 2021 | Direct | ||
EXELIXIS, INC. | Pres, Prod Dev & Med Aff & CMO | Option (right to buy) | 0 | Jul 26, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
EXEL | EXELIXIS, INC. | Jul 26, 2021 | 2 | $168K | 4 | Jul 28, 2021 | Pres, Prod Dev & Med Aff & CMO |
EXEL | EXELIXIS, INC. | Jul 21, 2021 | 2 | $147K | 4 | Jul 23, 2021 | Pres, Prod Dev & Med Aff & CMO |
GNCA | GENOCEA BIOSCIENCES, INC. | Jul 1, 2021 | 1 | $0 | 4 | Jul 2, 2021 | Director |
EXEL | EXELIXIS, INC. | May 13, 2021 | 3 | -$2.35M | 4 | May 14, 2021 | Pres, Prod Dev & Med Aff & CMO |